Journal
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
Volume 40, Issue 12, Pages 543-548Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/jir.2020.0214
Keywords
SARS-CoV-2; COVID-19; interferon; immune evasion
Funding
- NIH [AI142759, AI134907, AI145617, UL1TR001439]
- Sealy & Smith Foundation
- John S. Dunn Foundation
- Amon G. Carter Foundation
- Gillson Longenbaugh Foundation
- Summerfield Robert Foundation
- Kleberg Foundation
Ask authors/readers for more resources
The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), warranting urgent study of the molecular mechanisms of SARS-CoV-2 infection and host immune response. Type I interferon (IFN-I) is a key component of host innate immune system responsible for eliminating the virus at the early stage of infection. In contrast, SARS-CoV-2 has evolved multiple strategies to evade innate immune response to facilitate viral replication, transmission, and pathogenesis. This review summarizes the recent progresses on SARS-CoV-2 proteins that antagonize host IFN-I production and/or signaling. These progresses have provided knowledge for new vaccine and antiviral development to prevent and control COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available